|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 2:** Main clinical and hematological features of JMML patients with *LIN28B* ddPCR analysis in total and by *LIN28B* expression group | | | | | | |
|
|  |  |  | **Total** | ***LIN28B*High** | ***LIN28B*Low** | **p** |
|  |  |  |
|  |  |  |  |  |  |  |
| **n** |  |  | 108 | 37 | 71 |  |
|  |  |  |  |  |  |  |
| **Sex Ratio (M/F)** | |  | 1,5 (66/43) | 2,1 (25/12) | 1,3 (41/31) |  |
|  |  |  |  |  |  |  |
| **Age at onset (years), median (min-max)** | | | 1,6 (0,05-15,7) | 3,1 (0,7-15,7) | 1,0 (0,05 - 15,7) | 0,0238 |
|  |  |  |  |  |  |  |
| **Peripheral blood, median (min-max)** | | |  |  |  |  |
|  | **WBC count, x109/L** | | 25,1 (4,0-102,0) | 23,7 (6,1-83) | 26,0 (4,0-102,0) |  |
|  | **Monocyte count, x109/L** | | 5,1 (0,9-35,7) | 5,6 (1,5-15) | 4,6 (0,9-35,7) |  |
|  | **Hb, g/dl** |  | 9,8 (4,3-13,1) | 9,9 (6,4-13,1) | 9,6 (4,3-13,1) |  |
|  | **Platelets count, x109/L** | | 69,5 (7-663) | 50 (12-375) | 84 (7-663) |  |
|  |  |  |  |  |  |  |
| **HbF elevated for age (children > 6m)** | | | 52/74 | 36/36 (100%) | 16/38 (42%) | <0,0001 |
|  | **if elevated, (%), median (min-max)** | |  | 32 (3-85) | 6 (2-14) | <0,0001 |
|  |  |  |  |  |  |  |
| **RAS pathway mutation** | | |  |  |  |  |
|  | ***NRAS*** |  | 24 (22%) | 7 (19%) | 17 (24%) | ns |
|  | ***KRAS*** |  | 17 (16%) | 3 (8%) | 14 (20%) | ns |
|  | ***PTPN11*** |  | 33 (30%) | 20 (54%) | 13 (18%) | 0,0003 |
|  | ***NF1*** |  | 10 (9%) | 6 (16%) | 4 (6%) | ns |
|  | ***CBL*** |  | 17 (16%) | 0 (0%) | 17 (24%) | 0,003 |
|  | **Other** |  | 7 (6%) | 1 (3%) | 6 (8%) | ns |
|  |  |  |  |  |  |  |
| **Additional alterations** | | |  |  |  |  |
|  | ***ASXL1*** |  | 11 (10%) | 7 (19%) | 4 (6%) |  |
|  | ***SETBP1*** |  | 7 (6%) | 3 (8%) | 4 (6%) |  |
|  | ***JAK3*** |  | 9 (8%) | 7 (22%) | 2 (3%) |  |
|  | **RAS double mutant** | | 13 (12%) | 9 (24%) | 4 (6%) |  |
|  | **Monosomy 7** |  | 16 (15%) | 2 (5%) | 14 (20%) |  |
|  | **≥ 1 additional alteration** | | 41 (38%) | 22 (60%) | 19 (27%) | 0,0018 |
|  |  |  |  |  |  |  |
| **Outcome, n (%)** | |  |  |  |  |  |
|  | **HSCT** |  | 74 (69%) | 32 (86%) | 42 (60%) | 0,0034 |
|  | **Watch and Wait strategy** | | 29 (27%) | 0 (0%) | 29 (41%) | <0,0001 |
|  | **Relapse after HSCT** | | 17 (16%) | 13 (35%) | 4 (6%) | 0,0002 |
|  | **Alive at last follow up** | | 81 (76%) | 20 (54%) | 62 (86%) |  |
|  | **Lost to Follow-Up** | | 1 (1%) | 1 (3%) | 0 (0%) |  |
|  |  | |  |  |  |  |

WBC: white blood cell; HbF: fetal hemoglobin; ns: non-significant; HSCT: hematopoietic stem cell transplantation